These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 22694929)

  • 1. Methadone dose, take home status, and hospital admission among methadone maintenance patients.
    Walley AY; Cheng DM; Pierce CE; Chen C; Filippell T; Samet JH; Alford DP
    J Addict Med; 2012 Sep; 6(3):186-90. PubMed ID: 22694929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Take-home "privileges" for methadone maintenance patients: policies versus practices.
    Newman RG
    J Addict Med; 2012 Dec; 6(4):318; author reply 318. PubMed ID: 23131801
    [No Abstract]   [Full Text] [Related]  

  • 3. Supervised daily consumption, contingent take-home incentive and non-contingent take-home in methadone maintenance.
    Gerra G; Saenz E; Busse A; Maremmani I; Ciccocioppo R; Zaimovic A; Gerra ML; Amore M; Manfredini M; Donnini C; Somaini L
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):483-9. PubMed ID: 21147192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment: results from a population-based retrospective cohort study.
    Nosyk B; Sun H; Evans E; Marsh DC; Anglin MD; Hser YI; Anis AH
    Addiction; 2012 Sep; 107(9):1621-9. PubMed ID: 22385013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Achievement of take-home dose privileges is associated with better-perceived sleep and with cognitive status among methadone maintenance treatment patients.
    Peles E; Schreiber S; Domany Y; Sason A; Tene O; Adelson M
    World J Biol Psychiatry; 2014 Dec; 15(8):620-8. PubMed ID: 24666249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: A mixed methods analysis.
    Hoffman KA; Foot C; Levander XA; Cook R; Terashima JP; McIlveen JW; Korthuis PT; McCarty D
    J Subst Abuse Treat; 2022 Oct; 141():108801. PubMed ID: 35589443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A qualitative study exploring the reason for low dosage of methadone prescribed in the MMT clinics in China.
    Lin C; Detels R
    Drug Alcohol Depend; 2011 Aug; 117(1):45-9. PubMed ID: 21310554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with methadone maintenance therapy discontinuation among people who inject drugs.
    Lo A; Kerr T; Hayashi K; Milloy MJ; Nosova E; Liu Y; Fairbairn N
    J Subst Abuse Treat; 2018 Nov; 94():41-46. PubMed ID: 30243416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors affecting the dose of methadone among patients receiving methadone maintenance therapy in Taiwan.
    Li DJ; Chung KS; Wu HC; Hsu CY; Yen CF
    Am J Addict; 2018 Apr; 27(3):225-230. PubMed ID: 29569392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased incidence of QT interval prolongation in a population receiving lower doses of methadone maintenance therapy.
    Roy AK; McCarthy C; Kiernan G; McGorrian C; Keenan E; Mahon NG; Sweeney B
    Addiction; 2012 Jun; 107(6):1132-9. PubMed ID: 22168435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are 2 weeks of "take-home" privileges beneficial for patients' long-term outcome in a methadone maintenance treatment program?
    Adelson M; Schreiber S; Sason A; Peles E
    J Addict Med; 2014; 8(3):170-5. PubMed ID: 24440893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "It's like 'liquid handcuffs": The effects of take-home dosing policies on Methadone Maintenance Treatment (MMT) patients' lives.
    Frank D; Mateu-Gelabert P; Perlman DC; Walters SM; Curran L; Guarino H
    Harm Reduct J; 2021 Aug; 18(1):88. PubMed ID: 34391436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Earning "take-home" privileges and long-term outcome in a methadone maintenance treatment program.
    Peles E; Schreiber S; Sason A; Adelson M
    J Addict Med; 2011 Jun; 5(2):92-8. PubMed ID: 21769054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient satisfaction with methadone maintenance treatment: the relevance of participation in treatment and social functioning.
    Trujols J; Garijo I; Siñol N; del Pozo J; Portella MJ; Pérez de los Cobos J
    Drug Alcohol Depend; 2012 Jun; 123(1-3):41-7. PubMed ID: 22071121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methadone dosing and prescribed medication use in a prospective cohort of opioid-dependent pregnant women.
    Cleary BJ; Reynolds K; Eogan M; O'Connell MP; Fahey T; Gallagher PJ; Clarke T; White MJ; McDermott C; O'Sullivan A; Carmody D; Gleeson J; Murphy DJ
    Addiction; 2013 Apr; 108(4):762-70. PubMed ID: 23216809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19.
    Figgatt MC; Salazar Z; Day E; Vincent L; Dasgupta N
    J Subst Abuse Treat; 2021 Apr; 123():108276. PubMed ID: 33612201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methadone maintenance at different dosages for opioid dependence.
    Faggiano F; Vigna-Taglianti F; Versino E; Lemma P
    Cochrane Database Syst Rev; 2003; (3):CD002208. PubMed ID: 12917925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment outcome unaffected by initiation of full weekend closure of methadone maintenance treatment clinic.
    Peles E; Schreiber S; Adelson M
    J Addict Dis; 2014; 33(2):77-82. PubMed ID: 24717114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methadone and perinatal outcomes: a retrospective cohort study.
    Cleary BJ; Donnelly JM; Strawbridge JD; Gallagher PJ; Fahey T; White MJ; Murphy DJ
    Am J Obstet Gynecol; 2011 Feb; 204(2):139.e1-9. PubMed ID: 21145035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temporal associations between medication adherence for patients with schizophrenia and opioid dependence: A 17-year Canadian Cohort Study.
    Rezansoff SN; Moniruzzaman A; Somers JM
    Schizophr Res; 2019 Aug; 210():157-163. PubMed ID: 31202570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.